aNo patient was treated with concomitant nusinersen during the START phase 1 trial.
bTwo patients who did not enroll in the START long-term follow-up study are being followed up at the Nationwide Children’s Hospital Spinal Muscular Atrophy Clinic in Columbus, Ohio. Note that no visits were conducted in the START LTFU clinical trial from December 31, 2019, through June 11, 2020.
Milestones are shown for the 10 patients in the therapeutic-dose cohort who received dosing early and had low baseline motor function (blue quadrant), those who received dosing early and had high motor function (orange quadrant), and those who received dosing late (gray quadrant). Values in parentheses are the age at which the milestone was achieved (in months). Patients were grouped according to baseline motor function (Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores <20 points [low] or ≥20 points [high]) and age at dosing (<3 months [early] or ≥3 months [late]).5 This figure was adapted with author permission from Lowes LP et al.15
Statistical Analysis Plan
eFigure 1. Probability of permanent ventilation-free survival
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021;78(7):834–841. doi:10.1001/jamaneurol.2021.1272
What are the long-term safety and efficacy of onasemnogene abeparvovec in infants with spinal muscular atrophy type 1?
In this ongoing, long-term follow-up safety study of 13 infants with symptomatic spinal muscular atrophy type 1 treated with a single low or therapeutic dose of onasemnogene abeparvovec in the START phase 1 clinical trial, a favorable safety profile was observed for up to 6.2 years after dosing. For patients who received the therapeutic dose (which subsequently became the approved dose), onasemnogene abeparvovec provided sustained, durable efficacy, with all patients alive and without the need for permanent ventilation.
These results support the favorable long-term safety profile of onasemnogene abeparvovec and provide evidence of sustained clinical durability of the therapeutic dose.
This ongoing study assesses long-term safety and durability of response in infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene abeparvovec gene replacement therapy.
The primary objective of this ongoing study is to assess safety. The secondary objective is to determine whether developmental milestones achieved in the START phase 1 clinical trial were maintained and new milestones gained.
Design, Setting, and Participants
This study is an ongoing, observational, follow-up study for continuous safety monitoring for 15 years in patients from the START phase I study (conducted May 5, 2014, through December 15, 2017) at Nationwide Children’s Hospital in Columbus, Ohio. Participants were symptomatic infants with SMA type 1 and 2 copies of SMN2 previously treated with an intravenous dose of onasemnogene abeparvovec (low dose, 6.7 × 1013 vg/kg; or therapeutic dose, 1.1 × 1014 vg/kg) in START. Thirteen of 15 original START patients are included in this analysis; 2 patients’ families declined follow-up participation. Data were analyzed from September 21, 2017, to June 11, 2020.
Median time since dosing of 5.2 (range, 4.6-6.2) years; 5.9 (range, 5.8-6.2) years in the low-dose cohort and 4.8 (range, 4.6-5.6) years in the therapeutic-dose cohort.
Main Outcomes and Measures
The primary outcome measure was the incidence of serious adverse events (SAEs).
At data cutoff on June 11, 2020, 13 patients treated in START were enrolled in this study (median age, 38.9 [range, 25.4-48.0] months; 7 females; low-dose cohort, n = 3; and therapeutic-dose cohort, n = 10). Serious adverse events occurred in 8 patients (62%), none of which resulted in study discontinuation or death. The most frequently reported SAEs were acute respiratory failure (n = 4 [31%]), pneumonia (n = 4 [31%]), dehydration (n = 3 [23%]), respiratory distress (n = 2 [15%]), and bronchiolitis (n = 2 [15%]). All 10 patients in the therapeutic-dose cohort remained alive and without the need for permanent ventilation. Prior to baseline, 4 patients (40%) in the therapeutic-dose cohort required noninvasive ventilatory support, and 6 patients (60%) did not require regular ventilatory support, which did not change in long-term follow-up. All 10 patients treated with the therapeutic dose maintained previously acquired motor milestones. Two patients attained the new milestone of “standing with assistance” without the use of nusinersen.
Conclusions and Relevance
The findings of this ongoing clinical follow-up of patients with SMA type 1 treated with onasemnogene abeparvovec supports the long-term favorable safety profile up to 6 years of age and provides evidence for sustained clinical durability of the therapeutic dose.
ClinicalTrials.gov Identifier: NCT03421977.
Spinal muscular atrophy (SMA) is an autosomal recessive, neuromuscular disorder characterized by the dysfunction and loss of alpha motor neurons in the spinal cord, resulting in progressive muscle atrophy, weakness, and paralysis. Spinal muscular atrophy has a global disease incidence of approximately 1 in 12 000 and an overall carrier frequency of 1 in 54, which ranges from approximately 1 in 50 persons for White and Asian populations, to 1 in 100 persons in populations of African or Afro-American ancestry.1,2 Approximately 95% of all individuals with SMA have a homozygous deletion of survival motor neuron (SMN) 1.3 Spinal muscular atrophy is classified into 4 clinical groups (types 1 to 4) based on age at onset and maximum motor milestones achieved.3,4 Spinal muscular atrophy type 1 is the most severe and common form of the disease, accounting for 60% of cases. Individuals with SMA type 1 have onset of weakness in the first 6 months of infancy and never achieve the ability to sit independently. Prior to the availability of current therapies, SMA type 1 was associated with death or need for permanent ventilation (≥16 hours per day of noninvasive ventilation support for ≥14 days in the absence of an acute reversible illness or perioperatively) by 2 years of age.5 Median survival is 6 to 8 months in most survival studies of treatment-naive patients with SMA type 1.6,7
Onasemnogene abeparvovec is a single intravenous infusion of a recombinant adeno-associated virus serotype 9 vector-based gene therapy8 designed to deliver a full-length functional copy of the human SMN gene via a self-complementary adeno-associated virus serotype 9 vector8 that crosses the blood-brain barrier.9 The efficacy and safety of onasemnogene abeparvovec in patients with SMA type 1 was assessed in a 2-year, open-label, phase 1 study (START) conducted from May 5, 2014, through December 15, 2017.10,11 Data demonstrated that a 1-time infusion of onasemnogene abeparvovec low dose (6.7 × 1013 vg/kg of body weight) in 3 patients or therapeutic dose (1.1 × 1014 vg/kg) in 12 patients resulted in longer survival than observed in historical controls. Two of 3 patients in the low-dose cohort and all patients in the therapeutic-dose cohort were alive without the need for permanent ventilation at 24 months of age.8,10 Patients in the therapeutic-dose cohort also had significantly improved motor function and motor milestone achievements compared with historical cohorts. Eleven of 12 patients sat unassisted for ≥5 seconds, and 2 children pulled to a stand, stood, and walked independently.
Onasemnogene abeparvovec was generally well tolerated in these patients. The START long-term follow-up study (START LTFU hereafter) was designed to evaluate long-term serious adverse events (SAEs) and adverse events of special interest (AESIs) (ie, gene therapy–related adverse events, liver function enzyme elevations, new incidences of a malignancy or hematologic disorders, and new incidences or exacerbations of existing neurologic or autoimmune disorders). Of the known, identified potential risks related to onasemnogene abeparvovec, including hepatotoxicity, thrombocytopenia, cardiac adverse events, and events suggestive of neuronopathy, elevations in aminotransferase concentrations occurred in the time period proximate to administration.12 The question to be answered in the long-term follow-up of START is whether these elevations result in long-term sequelae. More recently, thrombotic microangiopathy has been identified as a new safety signal, with an apparent temporal relationship to time of administration.13 Thrombotic microangiopathy events have been observed 2 to 3 weeks after initiation of therapy. Given this new safety signal, ongoing monitoring is needed from all sources of safety data, including this and other long-term follow-up studies.
These long-term study data will help in the assessment of any potential long-term consequences (with reference to hematologic or autoimmune events). In addition, any new incidences of malignancy and new incidences or exacerbations of existing neurologic or autoimmune disorders are monitored. Although the aforementioned potential safety risks occur within a narrow window after administration, the long-term risks associated with onasemnogene abeparvovec are unknown to date.
To continue monitoring the safety and efficacy of onasemnogene abeparvovec in these patients, we undertook a long-term follow-up study (START LTFU) involving patients who had completed the phase 1 START study. Enrollment criteria were described in the original clinical trial.10 Here, we report interim results of this follow-up extension study (data cutoff on June 11, 2020).
The START LTFU is an ongoing, observational, long-term follow-up study of patients with a genetically confirmed diagnosis of SMA type 1, homozygous SMN1 exon 7 deletions, and 2 copies of SMN2 who received a low dose (6.7 × 1013 vg/kg) or a therapeutic dose (2.0 × 1014 vg/kg, subsequently determined to be 1.1 × 1014 vg/kg by direct measurement using the Digital Droplet polymerase chain reaction method). This dose was used in subsequent studies. Patients who received onasemnogene abeparvovec in the START study10 were eligible to enter the START LTFU. The primary objective of this ongoing analysis is to evaluate the long-term safety of onasemnogene abeparvovec, and the secondary objective is to determine whether the efficacy milestones achieved in START are maintained and whether new milestones are gained. The study consists of an initial 5-year phase, in which patients are assessed in the clinic annually, followed by annual phone assessments for an additional 10 years.
The study protocol (Supplement 1) was approved by the institutional review board at Nationwide Children’s Hospital in Columbus, Ohio. Study procedures were performed in accordance with principles of the Declaration of Helsinki14 and were consistent with the Good Clinical Practice Guidelines of the International Conference on Harmonization, applicable regulatory requirements, and Novartis Gene Therapies’ policy on bioethics. Written informed consent was obtained from the parents or legal guardians of the children at the last visit of the START study.
The primary outcome measures were the determination of safety on the basis of SAEs or AESIs. These AESIs included gene therapy–related delayed adverse events; liver function enzyme elevations; new malignancies; new incidence or exacerbation of a pre-existing neurologic disorder, or prior rheumatologic or other autoimmune disorder; or new incidence of hematologic disorder. Efficacy outcomes included motor-milestone achievement and assessment of ventilation. Milestone achievement was classified according to the World Health Organization Multicenter Growth Study definitions or Bayley Scales of Infant and Toddler Development, 3rd ed. New developmental milestones (ie, those that the patient had not previously achieved in the START study) were documented by video evidence captured either at the site or by a parent or legal guardian.
At each study visit in the initial 5-year phase of the study, we collected safety data through physical examinations, clinical laboratory evaluations, medical histories, and adverse event reporting. In addition, efficacy evaluations focused on pulmonary assessment (ie, ventilation) and a review of developmental milestones. As applicable, patients’ records from their local physicians were reviewed by the investigators. In the event of serious situations, such as the COVID-19 pandemic, that may have limited or prevented on-site study visits, alternative methods of conducting study assessments (eg, phone calls, virtual contacts or visits by site staff or home nursing service to the participant’s home) could be implemented. During the 10-year observational phase, caregivers and patients will be contacted at least once a year, and site staff will review a yearly questionnaire designed to elicit information regarding medical histories, SAEs, and clinical outcomes.
Detailed patient records include reports of SAEs related or unrelated to the study, AESIs, and concomitant medications, including other SMA treatments. Severity grades were defined per protocol: grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, or limiting self-care activities of daily living) and grade 4 (life-threatening consequences or urgent intervention indicated). Upper limits of normal for laboratory values included platelets (<75.0 × 109/L), neutrophils (<1.5 × 109/L), alanine aminotransferase (>3.0 × upper limit of normal), and aspartate aminotransferase (>3.0 × upper limit of normal).
No formal statistical testing was planned. Only descriptive statistics were performed. The statistical analysis plan is included in Supplement 2. Analyses for the present study were conducted from September 21, 2017, to June 11, 2020.
The first patient enrolled in the START LTFU on September 21, 2017. At the time of data cutoff (June 11, 2020), 13 of the original 15 patients had been enrolled in the long-term follow-up study, including 3 patients from the low-dose cohort and 10 from the therapeutic-dose cohort of the START study (Figure 1). Two patients’ families declined to continue participation into the START LTFU. These patients continued to be followed at the Nationwide Children’s Hospital Spinal Muscular Atrophy Clinic in Columbus, Ohio. Key demographic details and baseline clinical characteristics are summarized in Table 1. Seven patients (54%) were female, 12 (92%) were White, and 1 (8%) was Hispanic/Latino. At the baseline visit in the START LTFU, patient age ranged from 25.4 to 48 months (median, 38.9 months), and body weight ranged from 10.0 to 14.7 kg (median, 12.0 kg).
As of this data cutoff, the maximum follow-up was 6.2 years after dosing. Serious adverse events were reported for 8 patients (62%): 1 patient in the low-dose cohort and 7 patients in the therapeutic-dose cohort (Table 2). The most frequently reported SAEs were related to the underlying SMA disease process: acute respiratory failure (n = 4; terminology required by the US Food and Drug Administration to indicate that a child was hospitalized with a respiratory illness requiring invasive ventilation, but does connote the severest degree of respiratory decompensation or distress), pneumonia (n = 4), dehydration (n = 3), respiratory distress (n = 2), and bronchiolitis (n = 2). No SAE led to study discontinuation, and all were considered by the investigators to be unrelated to onasemnogene abeparvovec therapy. All SAEs were considered severe—all were grade 3, except for three grade 4 events in 1 patient in the low-dose cohort precipitated by an episode of hypoxemic respiratory failure due to a mucous plug that led to cardiac arrest, requiring resuscitation and intubation. The patient was subsequently extubated, and returned to baseline status.
No AESIs have been reported in the study to date. No AESIs were associated with liver enzyme elevations, hematology values, new malignancies, or autoimmune disorders. Upon review of laboratory data, we observed no trends in mean change from baseline for platelet or neutrophil counts. In addition, no patients shifted to a low value from baseline to the minimum platelet (75.0 × 109/L) or neutrophil count. No patient shifted from a low or normal baseline alanine aminotransferase concentration to a high maximum value during the study. One patient shifted from a low or normal baseline aspartate aminotransferase concentration to a high maximum value. This value remained high at the final value. No patients in the START LTFU met any of the criteria for potential hepatotoxicity or thrombotic microangiopathy at any time point.
As of June 11, 2020, the median time since dosing was 5.2 (range, 4.6-6.2) years in the overall population, 5.9 (range, 5.8-6.2) years in the low-dose cohort, and 5.0 (range, 4.6-5.6) years in the therapeutic-dose cohort (Table 3). All 10 patients in the therapeutic-dose cohort (eFigure in Supplement 3) were alive and did not require permanent ventilation; all 3 of the patients in the low-dose cohort remain alive, and 2 of these 3 remain free of permanent ventilation. At baseline, 6 of the 10 patients in the therapeutic-dose cohort did not require regular ventilatory support. No patient in this cohort has initiated new mechanical respiratory support to date during the follow-up study. The remaining 4 patients in this cohort had required noninvasive ventilatory support in the START study and maintained this requirement in the START LTFU, with no decline in their respiratory status or increased need for baseline respiratory support.
Two of the 10 patients in the therapeutic-dose cohort attained the new video-confirmed motor milestone of standing with assistance since completing the START study (Figure 2),15 both of which were confirmed by a central reviewer. In the remaining 8 patients of the cohort, all motor milestones attained in the START study were maintained, with no regression or loss of function. The ages at which these milestones were achieved are also provided in Figure 2.
As of June 11, 2020, 7 of the 13 patients were receiving concomitant nusinersen (all 3 patients in the low-dose cohort and 4 of the 10 patients in the therapeutic-dose cohort) in an attempt to maximize benefit and not because of a loss in motor function or perceived regression. Six patients in the therapeutic-dose cohort were recorded as receiving no further treatment for SMA apart from onasemnogene abeparvovec more than 4 years after onasemnogene abeparvovec dosing. The 2 patients in the therapeutic-dose cohort, who achieved the new milestones in the START LTFU, did not receive nusinersen at any point.
In the phase 1 START study, a single intravenous dose of onasemnogene abeparvovec gene replacement therapy extended survival, as evidenced by a median age at the last pulmonary assessment of 30.8 months for the low-dose cohort and 25.7 months for the therapeutic-dose cohort, and improved motor function in patients with SMA type 1.10 The current study provides long-term follow-up data in patients from the START study. To our knowledge, and based on a search of the literature, we believe this to be longest follow-up of gene therapy published to date.
In this first analysis of data from this ongoing START LTFU study, onasemnogene abeparvovec had a favorable safety profile for up to 6.2 years after dosing, with no new safety concerns or treatment-related SAEs reported during long-term follow-up. The SAEs reported during long-term follow-up were consistent with those previously observed with onasemnogene abeparvovec. No AESIs have been reported in the study, including liver function enzyme elevations, new incidences of malignancy or hematologic disorders, and new incidences or exacerbations of existing neurologic or autoimmune disorders.
Onasemnogene abeparvovec, at the therapeutic dose, maintained a durable response in patients up to 5.6 years after dosing, as of the June 11, 2020, data cutoff, which is unmatched in the natural history of patients with SMA. All 10 patients in the therapeutic-dose cohort and 2 of the 3 patients in the low-dose cohort were alive and did not require permanent ventilation at the time of this analysis. To date, no patient has initiated new mechanical respiratory support or required increased baseline respiratory support during long-term follow-up. In addition, motor milestones achieved in the START study have been maintained during long-term follow-up, with 2 patients in the therapeutic-dose cohort attaining the new milestone of standing with assistance, which can only be attributed to the long-term clinical durability of onasemnogene abeparvovec, as neither patient had received additional SMN protein-producing therapies.
The timing of drug intervention is critical in treating SMA, regardless of disease severity.3 In patients with more severe forms of SMA, irreversible loss of motor neurons starts in the prenatal period and progresses rapidly thereafter.16 In addition, preclinical studies have suggested that drug intervention in the presymptomatic or early symptomatic period is likely to produce the best response to therapy.3,17-19 In the original START study, 2 children who received early dosing (ie, within 3 months of birth) with onasemnogene abeparvovec achieved the motor milestone of sitting unassisted within a timeline consistent with that in healthy children (4-9 months).15 In the current long-term follow-up study, all patients in the early and late dosing groups maintained the motor milestones gained in the original START study, and 1 patient in each group has acquired the new milestone of standing with support. These data highlight the long-lasting durability of SMA treatment, the importance of identifying affected infants in the early period, and the need for reliable and validated newborn screening assays.3
In addition to this long-term follow-up study, the efficacy and safety of onasemnogene abeparvovec is being evaluated in several ongoing or recently completed phase 3 studies, including the STR1VE-US,20 STR1VE-EU,21 STR1VE-AP,22 and SPR1NT23 studies. Also underway is the phase 4, observational, long-term follow-up LT-002 study,24 which is enrolling patients with SMA types 1, 2, or 3 who have participated in previous onasemnogene abeparvovec intravenous studies other than START. Results of these studies are pending.
This follow-up study is limited by the small sample size of the patient population and confounded by treatment with nusinersen for several patients. However, given that the 2 patients who acquired the new motor milestone of standing with assistance did not receive nusinersen at any time, this benefit can be attributed solely to onasemnogene abeparvovec. In addition, rather than all adverse events, only SAEs and AESIs were collected. The study could also be limited by the ongoing COVID-19 pandemic, which has caused disruptions to patients, researchers, and institutions and could affect future follow-up and data collection.25 Of note, no visits were conducted in START LTFU, from December 31, 2019, through June 11, 2020.
In this analysis of data from the ongoing, long-term follow-up of the START clinical trial, a single intravenous dose of onasemnogene abeparvovec in patients with SMA type 1 continued to have a monitorable and manageable safety profile for up to 6.2 years after dosing. To date, no treatment-related SAEs or AESIs have been reported during long-term follow-up. Onasemnogene abeparvovec provides sustained and durable efficacy in patients up to 6.2 years after dosing. Anticipated results from completed and ongoing phase 3 and 4 studies will further confirm the efficacy and safety of onasemnogene abeparvovec. Current evidence demonstrates that onasemnogene abeparvovec continues to have a favorable benefit-risk profile for the treatment of pediatric patients with SMA.
Accepted for Publication: March 12, 2021.
Published Online: May 17, 2021. doi:10.1001/jamaneurol.2021.1272
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2021 Mendell JR et al. JAMA Neurology.
Corresponding Author: Jerry R. Mendell, MD, Center for Gene Therapy, Nationwide Children’s Hospital, 700 Children’s Dr, Columbus, OH 43205 (email@example.com).
Author Contributions: Drs Meriggioli and Kleyn had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mendell, Al-Zaidy, Lowes, Alfano, Reash, Shell.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Mendell, Shell.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kleyn.
Administrative, technical, or material support: Mendell, Al-Zaidy, Lehman, McColly, Church.
Supervision: Mendell, Al-Zaidy, Church, Meriggioli, Shell.
Conflict of Interest Disclosures: Dr Mendell reported receiving personal compensation for clinical trial consulting and for serving on scientific advisory boards, as well as research support from Novartis Gene Therapies outside the submitted work. Dr Al-Zaidy reported receiving personal compensation for consulting from Novartis Gene Therapies, license/royalty payment from Milo Biotech, research funding from Novartis Gene Therapies and Catalyst, grants from AveXis Inc during the conduct of the study, and personal fees from AveXis Inc outside the submitted work. Ms Lehman reported receiving nonfinancial support from Sarepta and AveXis outside the submitted work; in addition, Ms Lehman had a patent and received licensing fees for Gene Therapy Immersion Training Program licensed to Sarepta. Dr Lowes reported receiving personal compensation for employment, consulting, scientific advisory board participation, speaking, or other activities from ATOM International; and licensing fees or royalties from Nationwide Children’s Hospital. Dr Shell reported receiving personal compensation for consulting from Novartis Gene Therapies during the conduct of the study. Dr Alfano reported receiving personal compensation for employment, consulting, scientific advisory board participation, speaking, or other activities from ATOM International; and licensing fees or royalties from Nationwide Children’s Hospital. Dr Reash reported receiving personal compensation for employment, consulting, or other activities from ATOM International and personal fees from Casimir, LLC outside the submitted work. No other disclosures were reported.
Funding/Support: The study was supported by Novartis Gene Therapies, Inc.
Role of the Funder/Sponsor: The Novartis Gene Therapies authors reviewed and provided feedback on the paper.
Meeting Presentations: Data from previous data cuts of this study were included as a poster or oral presentation at meetings for the Child Neurology Society, October 15-18, Chicago, Illinois; CureSMA, June 14-17, 2018, Dallas, Texas; the European Society of Gene and Cell Therapy, October 16-19, 2018, Lausanne, Switzerland; Société Française de Myologie, November 21-23, 2018, Brest, France; Società Italiana di Neurologia Pediatrica, October 17-20, 2018, Bologna, Italy; and SMA Europe, January 25-27, 2018, Krakow, Poland; American Academy of Neurology, May 4-10, 2019, Philadelphia, Pennsylvania; Associazione Italiana Miologia, June 5-8, Bergamo, Italy; Child Neurology Society, October 23-26, 2019, Charlotte, North Carolina; Canadian Neurological Sciences Federation, June 16-19, 2019, Montreal, Canada; CureSMA, June 28-July 1, 2019, Anaheim, California; Deutsche Gesellschaft für Kinder- und Jugendmedizin, September 11-14, 2019, Munich, Germany; European Pediatric Neurology Society, September 17-21, 2019, Athens, Greece; Sociedad Argentina de Neurología Infantil, October 17-19, 2019, Santa Fe, Argentina; Société Française de Myologie, November 20-22, 2019, Marseille, France; Società Italiana di Neurologia, October 12-15, 2019, Bologna, Italy; Società Italiana di Neurofisiologia Clinica, May 29-June 1, 2019, Rome, Italy; Société Française De Neurologie Pédiatrique, January 16-18, 2019, Strasbourg, France; World Congress of Neurology, October 27-31, 2019, Dubai, United Arab Emirates; World Muscle Society, October 1-5, 2019, Copenhagen, Denmark; American Academy of Neurology, April 25-May 1, 2020, virtual; British Paediatric Neurology Association, January 29-31, 2020, Belfast, United Kingdom; CureSMA, June 11-14, 2020, virtual; Deutsche Gesellschaft für Kinder- und Jugendmedizin, September 17-19, 2020, virtual; European Academy of Neurology, May 23-26, 2020, virtual; Muscular Dystrophy Association, June-August 2020, virtual; Sociedade Brasileira de Neurologia Infantil, November 19-21, 2020, virtual; Sociedad Española de Neurología Pediátrica, May 10-15, 2021, virtual (postponed from 2020); Société Française De Neurologie Pédiatrique, January 15-17, 2020, Toulouse, France; SMA Europe, February 5-7, 2020, Evry, France; and World Muscle Society, September 30-October 4, 2020, virtual.
Additional Contributions: We sincerely thank the patients and volunteers who participated in the START LTFU. The authors also thank Deepa H. Chand, MD, PhD, of Novartis Gene Therapies, Inc, for her critical review of the manuscript. Jamie Weaver, PhD (Ashfield Healthcare Communications) provided writing support and edited the authors’ drafts of the manuscript, and Andrea Michels (Ashfield Healthcare Communications) copyedited and styled the manuscript per journal requirements, with funding from Novartis Gene Therapies, Inc.